The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Travis Lee Steed - Barclays Bank PLC, Research Division - Analyst
: Congrats on the quarter. I appreciate the colors on the margin pressures, but I just want to make sure it's clear how we're thinking about how these
pressures flow through to 2023. It sounds like 50 basis points of incremental pressure at this point. But also, curious if you have any offsets like
pricing. It was kind of noticeable that you didn't put pricing in the press release this quarter for the first time. So curious how you're thinking about
that.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 03, 2022 / 12:30PM, ZBH.N - Q1 2022 Zimmer Biomet Holdings Inc Earnings Call
Question: Travis Lee Steed - Barclays Bank PLC, Research Division - Analyst
: Yes, I appreciate all that color. And Suky, one follow-up on China. I just want to make sure we're modeling that correctly. It sounds like it was 200
to 300 basis point headwind to total company organic growth this quarter, but that comes back in Q4. And if you just look at China volume with
the shutdowns, I'd love to hear how that's playing out in Q2 and the recovery there from a volume perspective.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 03, 2022 / 12:30PM, ZBH.N - Q1 2022 Zimmer Biomet Holdings Inc Earnings Call
Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
: Great. Maybe, I could ask, the S.E.T. business was the slowest grower this quarter. It's 25% of sales and we don't get geographic breakout or segments
there. I was hoping if you could walk us through sort of the different components and any geographic differences to point out? Just given that a
lot of your competitors called out extremities and sports medicine as positives this quarter.
Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
: And are you guys willing to give any ex China growth rates for extremities and trauma?
Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
: Great. And maybe, just one quick follow-up for me. As you think about China, it's a country with the difficult pathways forward with the no COVID
policy. I just want to make sure, are you assuming continued pressure from lockdowns through the rest of the year? Or are you assuming that it
resolves in the near term?
| 
